Macrophage-Drug Conjugates: A New Frontier in Cancer Treatment
/0 Comments/in Delivery, Preclinical Research/by MaxNew Nanoparticle Therapy Holds Promise for Prostate Cancer Patients
/0 Comments/in Delivery, Preclinical Research/by MaxTiny Robots Revolutionize Targeted Drug Delivery: Caltech’s Microscopic Marvels
/0 Comments/in Delivery, Preclinical Research/by MaxNext-Generation Cell-Penetrating Antibodies: A Potential Breakthrough in Cancer Treatment
/0 Comments/in Delivery, Preclinical Research/by MaxIn Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer
/0 Comments/in Delivery, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025